Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 15;18:10. doi: 10.1186/s13062-023-00365-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — Effect of anti-angiogenic treatment on vasculature of tumors. a Segmentation of the perfused vasculature in different tumors including lineup of treatment results with the two anti-angiogenic agents mG6-31 and axitinib. White arrows indicate larger areas void of perfused vessels. Grid scale: 50 µm. b Comparison of RM10 values between tumors and tumors treated with mG6-31 or axitinib. n ≥ 4. c Comparison of relative perfused vessel volume between tumors and tumors treated with mG6-31 or axitinib. n ≥ 4. d Tracing results of perfused vessels in 4T1 tumors after treatment with mG6-31 or axitinib. Vessel segments are displayed color-coded according to average diameters. Treatment did not result in a more homogeneous distribution of vessel diameters, but overall vessel diameter was increased. Grid scale: 50 µm. e Results from PCA of vascular parameters in normal organs and in the three tumor models after anti- angiogenic therapy with either mG6-31 or axitinib. Orientation of four highly ranked selected variables (blue arrows) are shown. Error bars: ± SEM. Asterisks display results from statistical tests with *: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001